* Cadus Pharmaceutical Corp., of Tarrytown, N.Y., said New York-based Hambrecht & Quist LLC, managing underwriter for Cadus'initial public offering, exercised its option to purchase an additional412,500 shares. On July 7, 1996, Cadus sold 2.75 million shares at$7 each.

* Cephalon Inc., of West Chester, Pa., and Chiron Corp., ofEmeryville, Calif., initiated registration for an expanded accessprogram to make limited supplies of Myotrophin (rhIGF-1) availableto amyotrophic lateral sclerosis patients. The expanded accessprogram was cleared by the FDA under a treatment investigationalnew drug protocol.

* Lidak Pharmaceuticals Inc., of La Jolla, Calif., began the first oftwo additional Phase III trials of n-docosanol (Lidakol) for topicaltreatment of oral herpes. The two double-blind, placebo-controlledstudies will involve 500 patients and a primary endpoint of time tohealing. The placebo control in the previous study producedunexpected activity against herpes, resulting in lack of statisticalsignificance. The control vehicle was changed.

* Neurocrine Biosciences Inc., of San Diego, was awarded a$750,000 Phase II Small Business Innovation Research grant toexpand development of an automated combinatorial chemistrytechnology that can produce highly purified small organic molecules.It was the company's eighth SBIR grant.

* Xoma Corp., of Berkeley, Calif., announced completion of the firstinterim analysis for its ongoing 400-patient Phase II trial testingNeuprex to treat complications associated with acute blood loss. Anindependent board reviewed data from the first 100 patients andconcluded there were no safety concerns. Another analysis will lookat safety and efficacy data on the first 200 patients. That analysisalready is under way.

* Sugen Inc., of Redwood City, Calif., reported in the Aug. 1, 1996,issue of Cancer Research that small molecule drug candidatestargeting the Flk-1/KDR TK pathway can block the formation ofblood vessels. The preclinical work suggested the compoundsblocked vascular endothelial growth factor-dependent angiogenesisas well as vascular permeability. Human endothelial cells also wereprevented from undergoing cell division.


August 2, 1996

Vol. 7, No. 150


* CytoTherapeutics Inc., of Providence, R.I., appointed SandraLehrman president and chief operating officer.

* IBEX Technologies Inc., of Montreal, appointed Paul Silver vicepresident and director of preclinical research and Richard Vickersvice president of business development.

* Targeted Genetics Corp., of Seattle, named to its board of directorsMark Richmond, former executive with Glaxo Wellcome plc, ofLondon; Austin Long, of the University of Texas InvestmentManagement Co., of Austin; and Martin Sutter, of The Woodlands-Essex Venture Partners L.P., of Houston.

* Theratechnologies Inc., of Montreal, named to its scientificadvisory board Howard Fine, director of the brain tumor program atthe Dana-Farber Cancer Institute in Boston.

(c) 1997 American Health Consultants. All rights reserved.